ライフサイエンスコーパス: nasal

1 ion of a temporal (2,000 cells/mm(2) ) and a nasal (1,800 cells/mm(2) ) area embedded within a well-d

2 8.13 degrees ), PD values decreased in lower nasal (ADSP: -0.11 dB) and increased in upper temporal V

3 and LMW agents by SIC induced a differential nasal airway response including acute-phase reactants pr

4 Nasal allergen challenge (NAC) is a human model of aller

5 To assess the role of ILC2s during nasal allergen challenge in subjects with allergic rhini

6 Nasal allergen challenge was performed before treatment,

7 Nasal allergen challenges (NACs) and allergic biomarker

8 local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses tha

9 ivitis Quality of Life Questionnaire (RQLQ), nasal allergen provocation test (NAPT), skin testing, se

10 Nasal allergen provocation tests (NAPT) with Dermatophag

11 Assessment of safety, pharmacodynamics and nasal allergic reactivity following repeated weekly intr

12 We concluded that the modified preserved nasal and lacrimal mucosal flap technique in EES-DCR for

13 Modified preserved nasal and lacrimal mucosal flap technique in EES-DCR was

14 very 10 minutes during exposures, along with nasal and respiratory parameters.

15 Nasal and serum IFN-inducible protein 10 (IP-10) were me

16 Dose-related increases in nasal and serum IP-10 were observed 24 hours after doses

17 n unconventional natural gas development and nasal and sinus, migraine headache, and fatigue symptoms

18 alanced apoptosis and Pax2 expression in the nasal and temporal edges of the fissure.SIGNIFICANCE STA

19 [excluding SND]); choroidal thickness (CT); nasal and temporal retinal thickness (RT) at 500 mum and

20 arents, reviewed medical records, and tested nasal and throat swabs for EV-D68 using real-time revers

21 Pooled nasal and throat swabs were tested using multiplex real-

22 The nasal area may assist with detection of approaching obje

23 hile resolution of the horizontal streak and nasal area may help the discrimination of objects (preda

24 l area, 1,800 cells/mm(2) ), 7.7 cycles/deg (nasal area, 1,700 cells/mm(2) ), and 4.2 cycles/deg (hor

25 erformed by means of molecular techniques in nasal aspirated samples at birth.

26 ochemistry in cryostat sections of bronchial/nasal biopsies obtained from 33 SAs (21 frequent exacerb

27 (P < .01) of IL-17F(+) and IL-21(+) cells in nasal biopsies were observed in SAs compared with MAs.

28 8 (TRPM8); and nerve growth factor (NGF) in nasal biopsy specimens.

29 l VAS symptoms (rhinorrhea, mucus in throat, nasal blockage, and sense of smell), patient-reported ou

30 acial dysmorphisms (hypertelorism, depressed nasal bridge, frontal bossing), and postaxial polydactyl

31 To study IL-17-related cytokines in nasal/bronchial biopsies from controls and mild asthmati

32 e cutoff values of bronchial neutrophils and nasal/bronchial IL-17F for discriminating between asthma

33 dhood-onset severe asthma were identified in nasal brushings (5 signatures), sputum (3 signatures), a

34 on the total RNA of induced sputum (n = 83), nasal brushings (n = 41), and endobronchial brushings (n

35 on and gene expression of mucin 4 (MUC4), in nasal brushings from a separate validation cohort expose

36 RATIONALE: High-flow nasal cannula (HFNC) improves the clinical outcomes of n

37 hed patients who were treated with high-flow nasal cannula and those who were intubated at acute resp

38 d and 43 (25.3%) were treated with high-flow nasal cannula at acute respiratory distress syndrome ons

39 High-flow nasal cannula is increasingly used in the management of

40 designed to assess the effects of high-flow nasal cannula on indexes of respiratory effort (i.e., es

41 Either high-flow nasal cannula or mechanical ventilation was initiated, a

42 The results suggest that these high-flow nasal cannula patients should be considered as acute res

43 fter propensity score matching (39 high-flow nasal cannula patients vs 39 mechanical ventilation pati

44 bilateral infiltrates treated with high-flow nasal cannula presented a similar pattern of biomarkers

45 High-flow nasal cannula therapy and continuous positive airway pre

46 High-flow nasal cannula, when set at 60 L/min, significantly reduc

47 e positive pressure ventilation or high-flow nasal cannula.

48 ability and comfort suggested that high-flow nasal cannulae are associated with improved patient comf

49 High-flow nasal cannulae are used in adults with or at risk of acu

50 High-flow nasal cannulae seem well tolerated by patients.

51 When high-flow nasal cannulae were compared with usual care, there was

52 trials comparing administration of high-flow nasal cannulae with usual care (i.e., conventional oxyge

53 0.58-1.17) or rate of intubation (high-flow nasal cannulae, 119/1,207 [9.9%] vs usual care, 204/1,30

54 re was no difference in mortality (high-flow nasal cannulae, 60/1,006 [6%] vs usual care, 90/1,106 [8

55 Livestock-associated S. aureus nasal carriage predominated among IHO workers.

56 S. aureus nasal carriage prevalence was higher among IHO (53%) com

57 MDRSA nasal carriage prevalence was similar among IHO workers

58 fidence interval (CI): 1.07, 1.83], but MRSA nasal carriage prevalence was uncommon (2-3%) in IHO and

59 Median nasal carriage rate of S aureus in health-care workers a

60 B ligand binding activity compared to normal nasal carriage strains.

61 lates with protection against sepsis but not nasal carriage.

62 gh mitral cell counts and a greatly enlarged nasal cavity likely reflects a highly sensitive olfactor

63 Here, we reconstruct the internal nasal cavity of a Neanderthal plus two representatives o

64 isolated from infected AD skin than from the nasal cavity of healthy children.

65 main fully active in mouse lungs but not the nasal cavity, demonstrating that PlrS coordinates virule

66 includes epithelial cancers of the oral and nasal cavity, larynx, and pharynx and accounts for appro

67 itial uptake of aerosolized SCHU S4 from the nasal cavity, lungs, and possibly the gastrointestinal t

68 anatomical sites including the oral cavity, nasal cavity, pharynx, and larynx.

69 washed out by the injection of PBS to mouse nasal cavity, the response of MOR161-2 to acetophenone w

70 eurons (OSNs), which detect odors within the nasal cavity, would provide insight into the etiology of

71 midline to separate the oral cavity from the nasal cavity.

72 osal and systemic compartments and increases nasal CD8alpha(+) cell numbers.

73 Nasal cell samples may be informative about processes in

74 es from asthmatic patients and primary human nasal cells and used murine models of allergic asthma, a

75 ls/responses and gene expression patterns in nasal cells were largely concordant between M+ and M- pa

76 NA sequencing-derived expression profiles of nasal cells, before and after HDM exposure.

77 tolerated and reduced allergic reactivity to nasal challenge for 3 weeks post-treatment.

78 also expresses a neuraminidase, exacerbates nasal colonization and disease by S. pneumoniae, in part

79 are impaired in their ability to cause both nasal colonization and middle ear infection.

80 gen-matched strains but reduced or prevented nasal colonization by all 4 isolates with multiple cross

81 The respective nasal colonization rates were 11.1%, 6.7%, and 9.7%.

82 large part because of the high prevalence of nasal colonization with the pneumococcus in children.

83 sing a "humanized" transgenic mouse model of nasal colonization, we took a systematic approach to est

84 heral blood and inflammatory response in the nasal compartment, coupled with upregulation of genes th

85 ute for vaccinating infants, who may develop nasal congestion as a result of intranasal vaccination.I

86 exposure to seasonal pollen causes itching, nasal congestion, and repeated sneezing, with profound e

87 me, with a large increase in the duration of nasal continuous positive airway pressure.

88 Topical nasal corticosteroids are the treatment of choice for mo

89 s become persistent carriers, as assessed by nasal cultures, with many individuals colonised for deca

90 enge model, with flow cytometric analysis of nasal curettage samples, to assess the recruitment of IL

91 e model expressing KRAS(G12D) in the lung by nasal delivery of adenoviral Cre recombinase (Cre), here

92 results establish SMCHD1 as a key player in nasal development and provide biochemical insight into i

93 r more than 10 days, high fever and purulent nasal discharge or facial pain lasting for at least 3 co

94 pared to satisfy regulatory requirements for nasal dosage forms and the polymer nanoparticles alone w

95 se effects of CPAP and MADs included oral or nasal dryness, irritation, and pain, among others.

96 81 patients attending the outpatient clinic, nasal endoscopy changed classification in only four pati

97 icosteroid resistance was evaluated by using nasal endoscopy.

98 ant asthma-associated methylation changes in nasal epithelia of adult white asthmatic patients.

99 llergic inflammatory mediators in modulating nasal epithelial barrier integrity in the pathophysiolog

100 e upper airways represented by primary human nasal epithelial cells (HNECs) and murine nasal epitheli

101 an nasal epithelial cells (HNECs) and murine nasal epithelial cells (MNECs) and isolated murine trige

102 nor samples of in vitro-differentiated human nasal epithelial cells cultured at air-liquid interface.

103 Primary nasal epithelial cells from asthmatic patients intrinsic

104 Moreover, nasal epithelial cells from the patient, or fibroblasts

105 Samples of nasal epithelial cells placed in water are recorded by h

106 Air-liquid interface cultures of primary nasal epithelial cells were used to measure transepithel

107 of ENaC activity by short palate, lung, and nasal epithelial clone 1, known as SPLUNC1.

108 ating all of the cell types found within the nasal epithelium.

109 y biology independently provided evidence of nasal evolution, suggesting that adaptive explanations r

110 Rdh10, Fgf8 is ectopically expressed in the nasal fin.

111 n 12 months, and use of accessory muscles or nasal flaring.

112 mentary right maxilla preserving part of the nasal floor and two fragmentary molars.

113 nakes or neutral images into the temporal or nasal hemifield.

114 and the association between the reduction in nasal hyperreactivity (NHR) and response to capsaicin tr

115 osinophils/CD4(+)/CD8(+) cells and bronchial/nasal IL-17F(+) cells.

116 th the optimized GC-coated LPN adjuvant upon nasal immunization of mice with the recombinant Ct fusio

117 We sought to examine the role of SP in nasal infection by assessing the release of SP in respon

118 There was no evidence of nasal inflammation.

119 as Tw Pdi, but the predictive power of sniff nasal inspiratory pressure was also excellent.

120 The nasal instillation of only the KLK5-treated virus result

121 rates (GIRs) had to be increased more after nasal insulin than after placebo to maintain euglycemia

122 was more pronounced after administration of nasal insulin than after placebo.

123 Nasal intermittent positive pressure ventilation was sup

124 c in vitro but it increases the width of the nasal lamina propria when delivered intranasally.

125 Nasal lavage (NL) samples from 20 subjects who were expo

126 We sought to compare MP types and levels in nasal lavage fluids (NLFs) from controls and patients wi

127 Nasal lavage for flow cytometry and nasal swabs for vira

128 Nasal levels of selected allergic biomarkers demonstrate

129 Soluble mediators in the nasal lining fluid were measured using nasosorption.

130 While the nasal location of the CRVT in the prelamina has been ass

131 tein was also measured by ELISA in bronchial/nasal lysates and by immunohistochemistry in bronchial t

132 TA imaging of the superior, inferior, and/or nasal macula.

133 cally plausible, were also obtained for rare nasal melanoma and mesothelioma.

134 s aureus strains are often part of the human nasal microbiome, and this carrier state has often been

135 a had lower alpha- and beta-diversity of the nasal microbiota as compared with healthy control childr

136 Alterations in nasal microbiota but not of throat microbiota were assoc

137 Asthma was mainly associated with an altered nasal microbiota characterized by lower diversity and Mo

138 survival in such landscapes, changes in the nasal morphology and/or function aimed to humidify and w

139 livers standardized allergens locally to the nasal mucosa allowing clinical symptoms and biospecimens

140 2 numbers change in peripheral blood and the nasal mucosa during COX-1 inhibitor-induced reactions in

141 ILC2s are recruited to the nasal mucosa during COX-1 inhibitor-induced reactions in

142 okines expression was amplified in bronchial/nasal mucosa of neutrophilic asthma prone to exacerbatio

143 H9N2:pH1N1 (P0) virus was restricted to the nasal mucosa, with no virus detected in the trachea or l

144 nd natural infection occurs through oral and nasal mucosal exposure to infectious prions.

145 nic wasting disease (CWD) prions by oral and nasal mucosal exposure, and studies of early CWD pathoge

146 The magnitude of increases in nasal mucosal ILC2 numbers positively correlated with ma

147 ILC2 numbers significantly increased in nasal mucosal samples and decreased in blood at the time

148 Weekly nasal mucus samples were analyzed for RVs, and respirato

149 There are numerous proteins in the nasal mucus, and they contribute to olfaction through va

150 Nasal MxA and viperin indexes were increased in symptoma

151 ional consequences of capsaicin treatment on nasal nerve activation and the association between the r

152 ar-old African gentleman presented with left nasal obstruction and epistaxis for 2 years and was diag

153 eep was impaired by troublesome symptoms and nasal obstruction.

154 c symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-ast

155 er filled 4 different VAS measuring overall, nasal, ocular, and asthma symptoms at least once.

156 A combined nasal-ocular score is calculated.

157 cular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms.

158 ; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus >/=3 nasal/oc

159 al/ocular symptoms; (v) rhinorrhea plus >/=3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasa

160 -CYP2A antibody were determined for lung and nasal olfactory mucosa (OM) from Cyp2abfgs-null, CYP2A13

161 relies on Wnt8b suppression by Foxg1 in the nasal optic stalk to maintain balanced apoptosis and Pax

162 all individual VAS symptom scores, and Sino-Nasal Outcome Test patient-reported outcome score in the

163 The Sino-Nasal Outcome Test score might be able to predict more s

164 The mean baseline Sino-Nasal Outcome Test score was higher in severe reactors c

165 High-flow nasal oxygen has recently shown survival benefits in uns

166 Ninety patients in each group (high-flow nasal oxygen or standard oxygen) were matched according

167 High-flow nasal oxygen was neither associated with a lower intubat

168 poxemic acute respiratory failure, high-flow nasal oxygen when compared with standard oxygen did not

169 stay, 127 patients (36%) received high-flow nasal oxygen whereas 226 patients received standard oxyg

170 e respiratory failure treated with high-flow nasal oxygen.

171 d no further narrowing beyond 1 month in the nasal (P = .133), temporal (P = .376), and inferior (P =

172 in 9 subjects they were concentrated in the nasal parafoveal area.

173 loss was more extensive in the temporal and nasal parafoveal subfields of the deep plexus with sickl

174 ucin 4 (MUC4)-tethered mucin is expressed in nasal polyp (NP) epithelial cells and upregulated under

175 based on a composite end point of endoscopic nasal polyp score and nasal polyposis severity visual an

176 sal polyposis severity VAS score, endoscopic nasal polyp score, all individual VAS symptom scores, an

177 sal polyposis severity VAS score, endoscopic nasal polyp score, improvement in individual VAS symptom

178 alveolar lavage fluid, lung tissue, or human nasal polyp tissue were analyzed by means of Western blo

179 human bronchial epithelial cells (NHBEs) and nasal polyp tissues.

180 ting eosinophils exhibited EETs in patients' nasal polyp tissues.

181 sophageal reflux (42.1%), sinusitis (37.9%), nasal polyposis (30.2%), and allergic conjunctivitis (30

182 erature about stem cells/progenitor cells in nasal polyposis and how this may be exploited in the dev

183 Patients with eosinophilic nasal polyposis frequently require surgery, and recurren

184 In patients with recurrent nasal polyposis receiving topical corticosteroids who re

185 patients aged 18 to 70 years with recurrent nasal polyposis requiring surgery.

186 There was a significant improvement in nasal polyposis severity VAS score, endoscopic nasal pol

187 Secondary end points included change in nasal polyposis severity VAS score, endoscopic nasal pol

188 nd point of endoscopic nasal polyp score and nasal polyposis severity visual analog scale (VAS) score

189 haracterized by 3 clinical features: asthma, nasal polyposis, and respiratory reactions to cyclooxyge

190 sthma Control Questionnaire, medication use, nasal polyposis, aspirin sensitivity and neutrophil/eosi

191 In nasal polyposis, little is known about stem cells/progen

192 olizumab versus placebo for severe bilateral nasal polyposis.

193 provide new treatment options for combating nasal polyposis.

194 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal

195 nd those with chronic rhinosinusitis without nasal polyps (CRSsNP; P < .01).

196 of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and those with chronic rhinosinusi

197 -L1 and PD-L2 in chronic rhinosinusitis with nasal polyps (CRSwNP) is poorly studied.

198 polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respirato

199 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

200 he European guidelines on rhinosinusitis and nasal polyps (EPOS 2012), CT is used as the main imaging

201 were purified with protein A/G columns from nasal polyps (NP), matching patient serum, and control s

202 t oncostatin M (OSM) levels are increased in nasal polyps (NPs) of patients with chronic rhinosinusit

203 LP) is known to be elevated and truncated in nasal polyps (NPs) of patients with chronic rhinosinusit

204 A subset of CRS patients develop nasal polyps (NPs), which are characterized by type 2 in

205 iseases, such as chronic rhinosinusitis with nasal polyps and asthma, show increased nasal Staphyloco

206 a severe form of chronic rhinosinusitis with nasal polyps in which nearly all patients express anti-S

207 isolate single SAE-specific B cells from the nasal polyps of 3 patients with aspirin-exacerbated resp

208 to severe bronchial hyperresponsiveness and nasal polyps were independent predictors of asthma persi

209 evere airway hyperresponsiveness, more often nasal polyps, and higher levels of blood neutrophils as

210 Charts with search terms for asthma, nasal polyps, and record of respiratory (cohort A) or un

211 have been long recognized, with and without nasal polyps, are each now known to be heterogeneous, ba

212 in patients with chronic rhinosinusitis with nasal polyps.

213 ed proliferation of mesenchyme in developing nasal processes and adjacent tissue.

214 pression AP2alpha is reduced specifically in nasal processes of Mllt10-KO embryos.

215 H3K79me level is significantly decreased in nasal processes of Mllt10-KO embryos.

216 expression of Vax1 in ectoderm of the medial nasal processes, the upper lip remained intact in mutant

217 These results show that local nasal production of CK12a contributes to antiviral immun

218 cm of water pressure was delivered via CPAP nasal prongs.

219 In children with viral bronchiolitis, nasal propionate levels were decreased and correlated wi

220 Our aim was to determine the nasal protein expression profiles of WRA caused by diffe

221 ein allergens and isocyanates elicit similar nasal proteome responses and the profiles of welders and

222 the inferior and superior quadrants, and the nasal quadrant showed the latest and least changes.

223 s 20 mm, P < .0001), and less involvement of nasal region (50% vs 23%, P < .0001).

224 py, compared with placebo, provides improved nasal response to allergen challenge at 3-year follow-up

225 ors have demonstrated the existence of local nasal responses in some patients with typical allergic r

226 t was the highest density of M4 cells in the nasal retina.

227 lone were found to be biocompatible, via the nasal route, on chronic dosing.

228 bronchial epithelial BEAS-2B cells and human nasal RPMI2650 cells in the presence of FA.

229 To study associations of both nasal S. aureus carriage and SE sensitization to allergi

230 Participants were tested for nasal S. aureus carriage, serum total IgE and specific I

231 )] in mattress dust and to a lower extent in nasal samples [richness aOR 0.63 = (0.38-1.06), Shannon

232 eviewed HCT recipients with HCoV detected in nasal samples by polymerase chain reaction (PCR).

233 DNA from mattress dust and nasal samples of 86 school age children was analyzed by

234 al diversity in mattress dust as compared to nasal samples suggests microbial involvement beyond mere

235 the association of richness with farming in nasal samples was restricted to a high gradient of farm

236 e agreement of richness between mattress and nasal samples, the association of richness with farming

237 Blood and nasal scrapings were collected at baseline, during react

238 equired high levels of bacterial shedding in nasal secretions and was temporally correlated with, and

239 Histamine as well as nasal secretions of AR but not idiopathic rhinitis patie

240 st, azelastine prevented the early effect of nasal secretions of AR patients on epithelial integrity.

241 Deviation of the nasal sector from the expected ISNT pattern was a major

242 f the study was to assess if the presence of nasal septal deviation and concha bullosa is connected w

243 Nasal septal deviation was found in 79.9% of computed to

244 Nasal septal deviation, contrary to concha bullosa, has

245 nockout, Panx1 knockout, and wild-type mouse nasal septal epithelial cells were grown at an air-liqui

246 Deviated nasal septum was the most frequent variation in patients

247 ial sutures, cranial base synchondroses, and nasal septum.

248 sting a local role for MGP in the developing nasal septum.

249 es (NACs) and allergic biomarker assessment (nasal, serum) were conducted at baseline, FUV1, FUV2 and

250 E formulations in subcutaneous injection and nasal spray such as pain, adverse side effects and poor

251 o-controlled randomized trial with capsaicin nasal spray was performed involving 33 patients with IR

252 othpastes, mouthwashes, lozenges, throat and nasal sprays, and as biocides.

253 with nasal polyps and asthma, show increased nasal Staphylococcus aureus colonization.

254 l (temporal, superotemporal, inferotemporal, nasal, superonasal, and inferonasal) BMO-MRW were measur

255 detect H3N2 IAVs directly from nasal wash or nasal swab samples collected from laboratory-challenged

256 hildren's Hospital; clinical staff collected nasal swab samples from 25 patients and then operated te

257 cts recorded symptoms and provided blood and nasal swab samples.

258 assay for the direct detection of MRSA from nasal swab specimens.

259 irs completed a questionnaire and provided a nasal swab which was analyzed for S. aureus, methicillin

260 We performed nasopharyngeal or nasal swabbing and/or serum sampling (n = 148) in Lancas

261 e-motif 21 (TRIM21) messenger RNA indexes in nasal swabs as potential biomarkers of viral respiratory

262 We examined the children and obtained nasal swabs for the detection of RSV during each respira

263 Nasal lavage for flow cytometry and nasal swabs for viral PCR were performed at enrollment a

264 y tract infections based on parent-collected nasal swabs over the winter months.

265 Nasal swabs were taken from health-care workers every 4

266 determined by culturing ear, umbilicus, and nasal swabs, and (iii) the distribution of GBS serotypes

267 ch as blood, probang samples, and saliva and nasal swabs, and herd-level samples, such as air samples

268 arance for the direct detection of MRSA from nasal swabs.

269 egments into proper alignment and to improve nasal symmetry in patients with cleft lip and palate.

270 Both doses showed a trend in reducing total nasal symptom score 15 minutes post-NAC at FUV1 and FUV2

271 Total nasal symptom scores (TNSS; range; 0 [best] to 12 [worst

272 Total symptom scores and total nasal symptom scores were recorded at time zero (0) and

273 entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (

274 tokine release syndrome AEs (CytoRS-AEs) and nasal symptoms were assessed.

275 Among secondary end points, nasal symptoms were worse in the intradermal treatment g

276 tic response, visual analog scale scores for nasal symptoms, self-reported NHR, and mRNA expression o

277 8.3 +/- 9.6, and 49.1 +/-8.6 degrees for the nasal, temporal and inferior quadrants (P < .001).

278 ere compared among these time points and the nasal, temporal, and inferior quadrants.

279 Drusen-like deposits were located in the nasal, temporal, inferior, superior, and central regions

280 ymptoms as compared with patients undergoing nasal/temporal LPI (8.4% vs. 9.5%; P = 0.7), nor did the

281 Superior LPI (n = 285) and nasal/temporal LPI (n = 274) patients were matched for a

282 ed to either bilateral superior or bilateral nasal/temporal LPI.

283 6) and greater total energy (P < 0.001) than nasal/temporal LPIs.

284 before LPI (15.8% for superior vs. 13.9% for nasal/temporal; P = 0.1) or any individual dysphotopsia

285 ember 2006 through May 2012), only 13 (0.3%) nasal/throat swabs were positive for influenza C.

286 er gingiva, widely spaced teeth, and a broad nasal tip.

287 mRNA and expression of IL-5 mRNA in control nasal tissue (r = 0.95, P < 0.0001) and in CRSwNP (r = 0

288 PD-1 expression was found in CRSwNP than in nasal tissue from controls.

289 Nasal tissue was obtained from patients with CRS and con

290 usen with crystalline appearance, and drusen nasal to the optic disc are more likely to have a rare v

291 Oxygen was given via nasal tubes at 3 L/min if baseline oxygen saturation was

292 Nasal vaccination with a live attenuated virus results i

293 all allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma sympto

294 (ADSP): -0.18 dB) and increased in the lower nasal VF region (ADSP: 0.14 dB).

295 Nasal viperin index was found to be a robust marker of v

296 y tract infection as well as in reducing the nasal viral load when administered via the subcutaneous

297 for respiratory symptoms, lung function, and nasal viral load.

298 While only 2/6 direct-contact pigs showed nasal virus excretion of H9N2:pH1N1 (P0) >/=five days, 4

299 t green dominated responses in the lower and nasal visual field and ultraviolet dominated responses i

300 y can rapidly detect H3N2 IAVs directly from nasal wash or nasal swab samples collected from laborato